Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 28, 2017

Primary Completion Date

July 5, 2019

Study Completion Date

July 11, 2019

Conditions

Healthy

Interventions

DRUG

LSD

0.025 mg LSD per os, single dose

DRUG

LSD

0.05 mg LSD per os, single dose

DRUG

LSD

0.1 mg LSD per os, single dose

DRUG

LSD

0.2 mg LSD per os, single dose

DRUG

LSD

0.2 mg LSD plus 40 mg ketanserin per os, single doses each

DRUG

Placebo

Capsules containing mannitol looking identical to the other drugs.

Trial Locations (1)

University Hospital, Basel

All Listed Sponsors

lead

University Hospital, Basel, Switzerland

OTHER

NCT03321136 - Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study) | Biotech Hunter | Biotech Hunter